Pasteurellosis Vaccine Commercialization: Physiochemical Factors for Optimum Production

Abstract

Pasteurella spp. are Gram-negative facultative bacteria that cause severe economic and animal losses. Pasteurella-based vaccines are the most promising solution for controlling Pasteurella spp. outbreaks. Remarkably, insufficient biomass cultivation (low cell viability and productivity) and lack of knowledge about the cultivation process have impacted the bulk production of animal vaccines. Bioprocess optimization in the shake flask and bioreactor is required to improve process efficiency while lowering production costs. However, its state of the art is limited in providing insights on its biomass upscaling, preventing a cost-effective vaccine with mass-produced bacteria from being developed. In general, in the optimum cultivation of Pasteurella spp., production factors such as pH (6.0–8.2), agitation speed (90–500 rpm), and temperature (35–40 °C) are used to improve production yield. Hence, this review discusses the production strategy of Pasteurella and Mannheimia species that can potentially be used in the vaccines for controlling pasteurellosis. The physicochemical factors related to operational parameter process conditions from a bioprocess engineering perspective that maximize yields with minimized production cost are also covered, with the expectation of facilitating the commercialization process.

Effects of Core Antigen Bacterin with an Immunostimulant on Piglet Health and Performance Outcomes When Challenged with Enteric and Respiratory Pathogens

“…Since pasteurellosis is such a highly contagious disease, affecting almost every animal species, vaccine design strategies that lead to improved, cross-protected vaccines offer the best method of effective control [ 7 , 8 ]. Current control measures can be expensive and have little efficacy, so recently conducted research has been producing more potent and targeted vaccines [ 9 , 10 ]. Recent studies involving the genetic, biochemical, and virulence factors of P. multocida and other Pasteurellaceae family members resulted in a greater understanding of the disease mechanisms and the development of new non-bacterin vaccines, many of which are now available in the community for animal use.…”

Efficiency of NHEJ-CRISPR/Cas9 and Cre-LoxP Engineered Recombinant Turkey Herpesvirus Expressing Pasteurella multocida OmpH Protein for Fowl Cholera Prevention in Ducks

“…Vaccination remains a vital and effective strategy for disease prevention, playing a crucial role in reducing economic losses in the poultry industry. However, currently available vaccines against fowl cholera, including bacterins, live attenuated vaccines, and traditional vaccines, have inherent limitations such as limited duration of immunity, safety concerns, and reduced efficacy [ 4 ]. Consequently, there is a pressing need to explore innovative vaccine design strategies capable of eliciting enhanced cross-protective immune responses, which hold the promise of overcoming these limitations and potentially revolutionizing fowl cholera prevention and control [ 5 ].…”